Key result
Tafamidis yields sustained stability and fewer heart failure hospitalizations in rare p.Val40Ile ATTR-CM.
Why the study?
There is an evidence gap regarding the long-term efficacy of tafamidis for the rare and aggressive p.Val40Ile mutation in hereditary transthyretin amyloid cardiomyopathy.
Does tafamidis improve clinical stability and reduce hospitalizations in patients with ATTR-CM harboring the aggressive p.Val40Ile mutation?
Case Report (n=1)
No
Does tafamidis improve clinical stability and reduce hospitalizations in patients with ATTR-CM harboring the aggressive p.Val40Ile mutation?
This case provides genotype-specific, real-world evidence supporting the long-term efficacy of tafamidis in stabilizing disease and reducing hospitalizations for patients with ATTR-CM harboring the highly penetrant p.Val40Ile mutation.
Supports tafamidis consideration in rare ATTR-CM variants; extends case evidence but leaves open need for prospective confirmation.
Aims/Background: This case report aims to illustrate the critical importance of a standardized diagnostic approach and genotype-specific therapy in hereditary transthyretin amyloid cardiomyopathy (ATTR-CM). It highlights the clinical challenge of diagnosing ATTR-CM amidst complex comorbidities and addresses the evidence gap regarding the long-term efficacy of tafamidis for the rare and aggressive p.Val40Ile (protein-level substitution of valine to isoleucine at codon 40) mutation. Case Presentation: A 72-year-old East Asian man with multiple comorbidities presented with refractory heart failure. Key clinical clues included the classic “red flag” of electrocardiogram (ECG)-echocardiogram discordance (low voltage with ventricular hypertrophy). Genetic testing identified the pathogenic p.Val40Ile transthyretin (TTR) mutation. Results: The diagnosis was confirmed non-invasively via cardiac magnetic resonance (CMR) and technetium-99m pyrophosphate scintigraphy. Following the initiation of tafamidis, the patient’s symptoms significantly improved. Over a two-year follow-up period, he sustained clinical stability with a marked reduction in heart failure-related hospitalizations. Conclusion: This report provides detailed case-based evidence supporting the long-term efficacy of tafamidis in stabilizing disease and improving prognosis for patients with ATTR-CM harboring the p.Val40Ile mutation. It underscores the value of timely diagnosis, genetic subtyping, and access to targeted therapy in altering the clinical course of this aggressive genotype.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) conducted a case report in Hereditary Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (n=1). Tafamidis was evaluated on Clinical stability and heart failure-related hospitalizations. Tafamidis therapy provided sustained clinical stability and significantly reduced heart failure hospitalizations over a two-year period in a patient with the rare and aggressive p.Val40Ile ATTR-CM mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: